Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib Maintenance in Inoperable Stage III NSCLC
NCT00153803Phase 3Completed
- Sponsor
- Dartmouth Health
- Start
- May 2005
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Dartmouth Health. Started May 2005; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00153803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00153803.